572 related articles for article (PubMed ID: 18158502)
1. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.
Cooper WO
J Cardiovasc Nurs; 2008; 23(1):20-4. PubMed ID: 18158502
[TBL] [Abstract][Full Text] [Related]
2. Major congenital malformations after first-trimester exposure to ACE inhibitors.
Cooper WO; Hernandez-Diaz S; Arbogast PG; Dudley JA; Dyer S; Gideon PS; Hall K; Ray WA
N Engl J Med; 2006 Jun; 354(23):2443-51. PubMed ID: 16760444
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.
Piper JM; Ray WA; Rosa FW
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):429-32. PubMed ID: 1495700
[TBL] [Abstract][Full Text] [Related]
4. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
de Leeuw PW
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1605-7. PubMed ID: 16901062
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
Schaefer C
Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
[TBL] [Abstract][Full Text] [Related]
6. Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy.
Bowen ME; Ray WA; Arbogast PG; Ding H; Cooper WO
Am J Obstet Gynecol; 2008 Mar; 198(3):291.e1-5. PubMed ID: 18191803
[TBL] [Abstract][Full Text] [Related]
7. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.
Tabacova S; Little R; Tsong Y; Vega A; Kimmel CA
Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):633-46. PubMed ID: 14762979
[TBL] [Abstract][Full Text] [Related]
8. [In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam?].
Bonnot O; Vollset SE; Godet PF; d'Amato T; Dalery J; Robert E
Encephale; 2003; 29(6):553-9. PubMed ID: 15029090
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid monotherapy in pregnancy and major congenital malformations.
Jentink J; Loane MA; Dolk H; Barisic I; Garne E; Morris JK; de Jong-van den Berg LT;
N Engl J Med; 2010 Jun; 362(23):2185-93. PubMed ID: 20558369
[TBL] [Abstract][Full Text] [Related]
10. [Teratogenic effects of ACE-inhibitors and angiotensin II receptor antagonists].
Sørensen AM; Christensen S; Jonassen TE; Andersen D; Petersen JS
Ugeskr Laeger; 1998 Mar; 160(10):1460-4. PubMed ID: 9520613
[TBL] [Abstract][Full Text] [Related]
11. ACE inhibitors and birth defects.
Prescrire Int; 2006 Dec; 15(86):223. PubMed ID: 17167930
[No Abstract] [Full Text] [Related]
12. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
Walfisch A; Al-maawali A; Moretti ME; Nickel C; Koren G
J Obstet Gynaecol; 2011 Aug; 31(6):465-72. PubMed ID: 21823839
[TBL] [Abstract][Full Text] [Related]
13. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Quan A
Early Hum Dev; 2006 Jan; 82(1):23-8. PubMed ID: 16427219
[TBL] [Abstract][Full Text] [Related]
14. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study.
Nezvalová-Henriksen K; Spigset O; Nordeng H
Headache; 2010 Apr; 50(4):563-75. PubMed ID: 20132339
[TBL] [Abstract][Full Text] [Related]
15. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study.
Li DK; Yang C; Andrade S; Tavares V; Ferber JR
BMJ; 2011 Oct; 343():d5931. PubMed ID: 22010128
[TBL] [Abstract][Full Text] [Related]
16. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study.
Nørgaard M; Pedersen L; Gislum M; Erichsen R; Søgaard KK; Schønheyder HC; Sørensen HT
J Antimicrob Chemother; 2008 Jul; 62(1):172-6. PubMed ID: 18400803
[TBL] [Abstract][Full Text] [Related]
17. Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible.
Shrim A; Berger H; Kingdom J; Hamoudi A; Shah PS; Koren G
Can Fam Physician; 2005 Oct; 51(10):1335-7. PubMed ID: 16250418
[TBL] [Abstract][Full Text] [Related]
18. Bupropion in pregnancy and the prevalence of congenital malformations.
Cole JA; Modell JG; Haight BR; Cosmatos IS; Stoler JM; Walker AM
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):474-84. PubMed ID: 16897811
[TBL] [Abstract][Full Text] [Related]
19. Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure.
Chisholm CA; Chescheir NC; Kennedy M
Am J Perinatol; 1997 Oct; 14(9):511-3. PubMed ID: 9394157
[TBL] [Abstract][Full Text] [Related]
20. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy.
Daniel S; Matok I; Gorodischer R; Koren G; Uziel E; Wiznitzer A; Levy A
J Rheumatol; 2012 Nov; 39(11):2163-9. PubMed ID: 22984274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
